A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease
ID Number 14-1411Principal Investigator(s)
Eliza B Geer
Department(s) or Division(s)
The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease.
Recruiting Patients: Yes